Literature DB >> 12125964

Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes.

Sabine Spiegl-Kreinecker1, Johanna Buchroithner, Leonilla Elbling, Elisabeth Steiner, Gabriele Wurm, Angelika Bodenteich, Johannes Fischer, Michael Micksche, Walter Berger.   

Abstract

The poor prognosis of glioma patients is partly based on the minor success obtained from chemotherapeutic treatments. Resistance mechanisms at the tumor cell level may be, in addition to the blood-brain barrier, involved in the intrinsic chemo-insensitivity of brain tumors. We investigated the expression of the drug-transporter proteins P-glycoprotein (P-gp) and multidrug-resistance protein 1 (MRP1) in cell lines (N = 24) and primary cell cultures (N = 36) from neuroectodermal tumors, as well as in brain tumor extracts (N = 18) and normal human astrocytes (N = 1). We found that a considerable expression of P-gp was relatively rare in glioma cells, in contrast to MRP1, which was constitutively overexpressed in cells derived from astrocytomas as well as glioblastomas. Also, normal astrocytes cultured in vitro expressed high amounts of MRPI but no detectable P-gp. Meningioma cells frequently co-expressed P-gp and MRP1, while, most of the neuroblastoma cell lines express higher P-gp but lower MRP1 levels as compared to the other tumor types. Both, a drug-exporting and a chemoprotective function of P-gp as well as MRP1 could be demonstrated in selected tumor cells by a significant upregulation of cellular 3H-daunomycin accumulation and daunomycin cytotoxicity via administration of transporter antagonists. Summing up, our data suggest that P-gp contributes to cellular resistance merely in a small subgroup of gliomas, but frequently in neuroblastomas and meningiomas. In contrast, MRP1 is demonstrated to play a constitutive role in the intrinsic chemoresistance of gliomas and their normal cell counterpart.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12125964     DOI: 10.1023/a:1015735815111

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells.

Authors:  Y Zhang; H Han; W F Elmquist; D W Miller
Journal:  Brain Res       Date:  2000-09-08       Impact factor: 3.252

Review 2.  Principles of treatment of malignant gliomas in adults: an overview.

Authors:  S A Azizi; C Miyamoto
Journal:  J Neurovirol       Date:  1998-04       Impact factor: 2.643

Review 3.  P-glycoprotein and multidrug resistance.

Authors:  M M Gottesman; I Pastan; S V Ambudkar
Journal:  Curr Opin Genet Dev       Date:  1996-10       Impact factor: 5.578

4.  Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.

Authors:  L Rieger; J Rieger; S Winter; J Streffer; P Esser; J Dichgans; R Meyermann; M Weller
Journal:  Acta Neuropathol       Date:  2000-05       Impact factor: 17.088

5.  Expression of multidrug resistance-associated protein (MRP) in human gliomas.

Authors:  M Mohri; H Nitta; J Yamashita
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

6.  MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors.

Authors:  K Tóth; M M Vaughan; N S Peress; H K Slocum; Y M Rustum
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

7.  Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells.

Authors:  W Berger; E Hauptmann; L Elbling; M Vetterlein; E M Kokoschka; M Micksche
Journal:  Int J Cancer       Date:  1997-03-28       Impact factor: 7.396

Review 8.  Anticancer drug resistance in primary human brain tumors.

Authors:  M Bredel
Journal:  Brain Res Brain Res Rev       Date:  2001-04

9.  Transient induction of the MRP/GS-X pump and gamma-glutamylcysteine synthetase by 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3- nitrosourea in human glioma cells.

Authors:  A Gomi; S Shinoda; T Masuzawa; T Ishikawa; M T Kuo
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

10.  Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells.

Authors:  Z Holló; L Homolya; T Hegedüs; B Sarkadi
Journal:  FEBS Lett       Date:  1996-03-25       Impact factor: 4.124

View more
  34 in total

Review 1.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

2.  Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.

Authors:  Gisela Natalia Castro; Niubys Cayado-Gutiérrez; Felipe Carlos Martín Zoppino; Mariel Andrea Fanelli; Fernando Darío Cuello-Carrión; Mayra Sottile; Silvina Beatriz Nadin; Daniel Ramón Ciocca
Journal:  Cell Stress Chaperones       Date:  2014-08-26       Impact factor: 3.667

Review 3.  The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease.

Authors:  Evan K Noch; Kamel Khalili
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

4.  In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma.

Authors:  Emilio Ciusani; Danilo Croci; Maurizio Gelati; Chiara Calatozzolo; Francesca Sciacca; Luisa Fumagalli; Marco Balzarotti; Laura Fariselli; Amerigo Boiardi; Andrea Salmaggi
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 5.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.

Authors:  Sagar Agarwal; Ramola Sane; Rajneet Oberoi; John R Ohlfest; William F Elmquist
Journal:  Expert Rev Mol Med       Date:  2011-05-13       Impact factor: 5.600

6.  Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine.

Authors:  Mine Erguven; Ayhan Bilir; Nuray Yazihan; Seval Korkmaz; Esin Aktas; Cem Ovalioglu; Tolga Dundar; Hakan Seyithanoglu
Journal:  Oncol Lett       Date:  2011-10-04       Impact factor: 2.967

Review 7.  Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.

Authors:  Yumi Yamamoto; Meindert Danhof; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-03-09       Impact factor: 4.009

8.  Potential role of Shh-Gli1-BMI1 signaling pathway nexus in glioma chemoresistance.

Authors:  M H Shahi; S Farheen; M P M Mariyath; J S Castresana
Journal:  Tumour Biol       Date:  2016-09-23

Review 9.  Determination and modelling of stereoselective interactions of ligands with drug transporters: a key dimension in the understanding of drug disposition.

Authors:  P Bhatia; M Kolinski; R Moaddel; K Jozwiak; I W Wainer
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

Review 10.  Brain endothelial cells as pharmacological targets in brain tumors.

Authors:  Michel Demeule; Anthony Régina; Borhane Annabi; Yanick Bertrand; Michel W Bojanowski; Richard Béliveau
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.